<DOC>
	<DOC>NCT00300560</DOC>
	<brief_summary>In patients with documented ESBL-producing E.coli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen.</brief_summary>
	<brief_title>Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli</brief_title>
	<detailed_description>In patients with documented ESBL-producing E.coli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen.The primary outcome is clinical response and secondary outcomes are microbiological response and adverse events.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>Age &gt; 18 yr. Hospitalized to Siriraj Hospital Infections with ESBLproducing E.coli or K.pneumoniae Consent informed consent Pregnancy or lactating mother Colistin allergy Neurologic diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>ESBL-producing E.coli Infections</keyword>
	<keyword>ESBL-producing Klebsiella pneumoniae Infections</keyword>
	<keyword>Colistin</keyword>
</DOC>